<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Discov Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Discov Oncol</journal-id><journal-title-group><journal-title>Discover Oncology</journal-title></journal-title-group><issn pub-type="epub">2730-6011</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40186678</article-id><article-id pub-id-type="pmc">PMC11972247</article-id>
<article-id pub-id-type="publisher-id">2240</article-id><article-id pub-id-type="doi">10.1007/s12672-025-02240-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Role of emodin to prevent gastrointestinal cancers: recent trends and future prospective</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Thakral</surname><given-names>Falak</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Prasad</surname><given-names>Bhairav</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sehgal</surname><given-names>Rippin</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Saurabh</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Ujjawal</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Bikram Jit</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Bunty</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Tuli</surname><given-names>Hardeep Singh</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Haque</surname><given-names>Shafiul</given-names></name><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ahmad</surname><given-names>Faraz</given-names></name><address><email>faraz.ahmad@vit.ac.in</email></address><xref ref-type="aff" rid="Aff10">10</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013qfkw58</institution-id><institution-id institution-id-type="GRID">grid.440699.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2197 9607</institution-id><institution>Department of Bio-Sciences and Technology, </institution><institution>Maharishi Markandeshwar Engineering College, Maharishi Markandeshwar (Deemed to Be University), </institution></institution-wrap>Mullana, Ambala, India </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03tjsyq23</institution-id><institution-id institution-id-type="GRID">grid.454774.1</institution-id><institution>Department of Biotechnology, </institution><institution>Chandigarh Group of Colleges, Landran, </institution></institution-wrap>Mohali, Punjab India </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03tjsyq23</institution-id><institution-id institution-id-type="GRID">grid.454774.1</institution-id><institution>Department of Biotechnology, </institution><institution>Ambala College of Engineering and Applied Research, Devsthali, </institution></institution-wrap>Ambala, Haryana 133101 India </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00xdn8y92</institution-id><institution-id institution-id-type="GRID">grid.412580.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2151 1270</institution-id><institution>Mata Gujri College, </institution></institution-wrap>Fatehgarh Sahib, Punjab India </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02kknsa06</institution-id><institution-id institution-id-type="GRID">grid.428366.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1773 9952</institution-id><institution>Department of Human Genetics and Molecular Medicine, </institution><institution>Central University of Punjab, </institution></institution-wrap>Bhatinda, 151001 India </aff><aff id="Aff6"><label>6</label>Mechanical Engineering Department, MM Engineering College, Maharishi Markandeshwar (Deemed to Be University), Mullana, Ambala, Haryana 133207 India </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03wqgqd89</institution-id><institution-id institution-id-type="GRID">grid.448909.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1771 8078</institution-id><institution>Department of Biotechnology, </institution><institution>Graphic Era (Deemed to Be University), </institution></institution-wrap>Dehradun, Uttarakhand India </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02bjnq803</institution-id><institution-id institution-id-type="GRID">grid.411831.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0398 1027</institution-id><institution>Department of Nursing, College of Nursing and Health Sciences, </institution><institution>Jazan University, </institution></institution-wrap>Jazan-45142, Saudi Arabia </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00b210x50</institution-id><institution-id institution-id-type="GRID">grid.442156.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9557 7590</institution-id><institution>School of Medicine, </institution><institution>Universidad Espiritu Santo, </institution></institution-wrap>Samborondon, 091952, Ecuador </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03tjsyq23</institution-id><institution-id institution-id-type="GRID">grid.454774.1</institution-id><institution>Department of Biotechnology, School of Bio Sciences and Technology (SBST), </institution><institution>Vellore Institute of Technology, </institution></institution-wrap>Vellore, 632014 India </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>16</volume><elocation-id>468</elocation-id><history><date date-type="received"><day>18</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>25</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Gastrointestinal malignancies are responsible for approximately 35% of all cancer-related deaths, underscoring the critical need to explore pharmacologically active molecules for chemoprevention. Emodin (1,3,8-trihydroxy-6-methylanthraquinone), a natural compound derived from traditional Chinese and Japanese medicine, has recently garnered significant attention for its potential anticancer properties. Emodin exerts its chemoprotective effects through a combination of antioxidative, anti-inflammatory, and anti-proliferative mechanisms. Research indicates that emodin inhibits cancer metastasis, disrupts cell cycle progression, and impairs cancer cell survival. These effects are mediated through the activation of the p38 MAPK/JNK1/2 signaling pathway, the upregulation of pro-apoptotic factors such as Bax/Bcl-2 and caspases, and the enhancement of reactive oxygen species (ROS) levels (Supplementary Fig.&#x000a0;1). To optimize emodin&#x02019;s therapeutic potential, it is crucial to further investigate its underlying mechanisms of action and develop advanced nano-targeted delivery systems to enhance its bioavailability. This review highlights emodin&#x02019;s promise as a chemopreventive agent for gastrointestinal cancers and emphasizes its potential for development into a novel clinical formulation.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s12672-025-02240-9.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Emodin</kwd><kwd>Gastrointestinal cancers</kwd><kwd>Phytochemicals</kwd><kwd>Anticancer properties</kwd><kwd>Nanoparticles</kwd></kwd-group><funding-group><award-group><funding-source><institution>Vellore Institute of Technology, Vellore</institution></funding-source></award-group><open-access><p>Open access funding provided by Vellore Institute of Technology.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par14">One of the most prevalent cancers in the world today is gastrointestinal cancer (GI). Among all cancers, GI ranks second in terms of mortality rates [<xref ref-type="bibr" rid="CR1">1</xref>]. GI causes major malignances over worldwide and which not fully elucidated. There are six major GI cancers identified by International classification of diseases (ICD 10th revision). The six major classes of GI are esophagus (EC), Gastric (GC), Liver (LC), Pancreatic (PC), colon and rectal cancer. Over 3 million deaths and 4.1 million new cases are caused by these tumours year worldwide [<xref ref-type="bibr" rid="CR2">2</xref>]. Each kind of GI cancer accounts for roughly 700,000 deaths annually [<xref ref-type="bibr" rid="CR3">3</xref>]. The most prevalent kind of tumours are GI malignancies, which often afflict both sexes. Cancer has become a more common cause of mortality and difficulty due to population expansion and ageing as well as inequality in cancer control. These cancers are currently being treated with cytotoxic chemotherapy, radiotherapy, immunotherapy, and/or surgery [<xref ref-type="bibr" rid="CR4">4</xref>]. There hasn't been much progress in addressing the prevalent off-target effects and acquired drug resistance that these treatment paradigms bring with them, despite the fact that they have definitely increased survival. Utilising natural substances has demonstrated potential in reducing the growth of tumours and mitigating side effects related to conventional chemotherapy treatments. Many naturally occurring substances have extremely wide pleiotropic effects, which makes them appealing candidates to target the various pathways causing cancer and adverse drug reactions [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par15">Emodin, an anthraquinone derived from Chinese herbs, has shown potential as a natural anti-cancer agent in pre-clinical trials for the treatment of several types of cancer, including those of the liver, pancreatic, gallbladder, stomach, colon, and lung [<xref ref-type="bibr" rid="CR6">6</xref>]. Chinese medicinal herbs contains emodin, which is utilized in traditional Chinese and Japanese medicine, include <italic>Rheum palmatum, Polygonum cuspidatum,</italic> and <italic>Cassia obtusifolia</italic> [<xref ref-type="bibr" rid="CR7">7</xref>]. Emodin has been shown by modern pharmacology to have a number of beneficial benefits, including anti-inflammatory, anti-tumor, anti-oxidant, laxative and hypoglycemic actions [<xref ref-type="bibr" rid="CR8">8</xref>]. Emodin&#x02019;s anti-tumor activities are achieved through altering several hallmarks of cancer, including as invasion and metastasis, tumour angiogenesis, epithelial-mesenchymal transition (EMT), cell growth (i.e., promotion of apoptosis, reduction of proliferation, and changed cellular redox status). It has been determined that emodin modulates a number of oncogenic signalling pathways and molecules, including as HIF-1&#x003b1;, NF-&#x003ba;B, HER-2, STAT3, AKT/mTOR, Wnt, p38/p53/Puma, and VEGFR-2 [<xref ref-type="bibr" rid="CR9">9</xref>].</p></sec><sec id="Sec2"><title>Chemistry and pharmacokinetics</title><p id="Par16">Emodin is a natural compound found in several plants, known as an anthraquinone. It has a variety of beneficial effects on health, offering several pharmacological activities [<xref ref-type="bibr" rid="CR10">10</xref>]. Structurally Emodin is 1,3,8-trihydroxy-6-methylanthraquinone (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR11">11</xref>].<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Emodin structure generated by chemdraw</p></caption><graphic xlink:href="12672_2025_2240_Fig1_HTML" id="MO1"/></fig></p><p id="Par17">A naturally occurring anthraquinone derivative called emodin has attracted a lot of interest due to its possible therapeutic benefits, especially when it comes to GI. [<xref ref-type="bibr" rid="CR12">12</xref>]. Pharmacokinetically, emodin exhibits a complex profile characterized by moderate absorption, extensive metabolism, and variable bioavailability [<xref ref-type="bibr" rid="CR13">13</xref>]. Upon oral administration, emodin is absorbed in the small intestine, but its bioavailability is often limited by poor solubility and rapid metabolism [<xref ref-type="bibr" rid="CR14">14</xref>]. In the liver, emodin is extensively metabolised in phases I and II, producing a number of metabolites, primarily glucuronides and sulfates, which are excreted via bile and urine [<xref ref-type="bibr" rid="CR10">10</xref>]. The enterohepatic recirculation of emodin and its metabolites contributes to a prolonged half-life, enhancing its therapeutic window [<xref ref-type="bibr" rid="CR15">15</xref>]. In the context of GI cancers, the distribution of emodin to the gastrointestinal tract is particularly advantageous, allowing for direct interaction with cancer cells in the stomach, colon, and rectum [<xref ref-type="bibr" rid="CR16">16</xref>]. Studies have shown that emodin can induce apoptosis, proliferation inhibition, and suppress metastasis of cancer cells through various molecular pathways, including the inhibition of NF-&#x003ba;B, PI3K/Akt [<xref ref-type="bibr" rid="CR17">17</xref>], and Wnt/&#x003b2;-catenin signaling [<xref ref-type="bibr" rid="CR18">18</xref>]. Despite these promising pharmacological activities, the clinical application of emodin is hampered by its pharmacokinetic limitations [<xref ref-type="bibr" rid="CR19">19</xref>]. Strategies such as nanoparticle delivery systems and structural modifications are being explored to enhance its solubility, stability, and bioavailability [<xref ref-type="bibr" rid="CR20">20</xref>]. Overall, understanding the pharmacokinetics of emodin is crucial for optimizing its therapeutic efficacy against GI cancers, paving the way for its potential incorporation into clinical practice.</p></sec><sec id="Sec3"><title>Biosynthesis of emodin</title><p id="Par18">Emodin, a naturally occurring derivative of methylanthraquinone, is widely distributed among higher plants, particularly within the families Polygonaceae, Fabaceae, and Rhamnaceae. Its presence has also been documented in various fungal genera, including <italic>Aspergillus</italic>, <italic>Penicillium</italic>, and <italic>Cladosporium</italic> [<xref ref-type="bibr" rid="CR21">21</xref>]. This compound is commonly found in plants alongside other structurally related anthraquinones, including rhein, chrysophanol, aloe-emodin, and physcion. The biosynthesis of anthranoids in plants is believed to involve octaketide synthase (OKS), a member of the type III polyketide synthase (PKS) enzyme superfamily. PKSs generate diverse polyketide scaffolds, including chalcone, stilbene, acridone, curcumin, and isocoumarin [<xref ref-type="bibr" rid="CR22">22</xref>]. Type III PKSs are homodimers with subunit masses of 40&#x02013;45&#x000a0;kDa. Structurally, type III PKSs are compact homodimeric proteins, with each monomer harboring an independent active site featuring a catalytic triad of cysteine (Cys), histidine (His), and asparagine (Asn). They catalyze the stepwise condensation of acetyl units from malonyl-CoA decarboxylation onto a starter CoA ester, resembling fatty acid biosynthesis. Their functional diversity arises from variations in starter molecule selection, the number of malonyl-CoA condensations, and cyclization mechanisms [<xref ref-type="bibr" rid="CR23">23</xref>]. Type III PKSs employ a straightforward strategy, priming with a monocarboxyl-CoA starter substrate followed by iterative decarboxylative condensations with dicarboxyl-CoA extenders to form a poly-&#x003b2;-keto intermediate. This intermediate can be cyclized or released as a linear product. Their versatility lies in the ability to accept diverse starter and extender substrates, enabling various condensation and elongation reactions explained in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>. OKS uses acetyl-CoA as a starter, sequentially condensing it with seven malonyl-CoA molecules to produce a linear octaketide intermediate. Oxidation of the central cyclohexadienone ring in emodin anthrone forms emodin.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Process of Biosynthesis of Emodin [<xref ref-type="bibr" rid="CR24">24</xref>]</p></caption><graphic xlink:href="12672_2025_2240_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec4"><title>Major gastrointestinal cancer</title><p id="Par19">According to numerous reports, cancer is the leading cause of death and the largest obstacle to raising life expectancy in both developed and developing countries. Numerous plants naturally contain emodin (1,3,8-trihydroxy-6-methylanthraquinone), an anthraquinone derivative with a wide range of biological activities, such as hepatoprotective, antibacterial, anti-inflammatory, and anticancer effects. Regarding a number of cancer types, such as colon cancer, breast cancer, cervical cancer, leukaemia, lung cancer, ovarian cancer, liver cancer, and pancreatic cancer, Emodin provides accurate results [<xref ref-type="bibr" rid="CR25">25</xref>]. Gastrointestinal (GI) cancers are one of the main cancers worldwide and pose a serious threat to human health. GI cancer account for 26% cancer incidence globally and 35% of all cancer related deaths. According to a 2018 survey, there were 3.4 million GI cancer deaths and 4.8 million new cases globally in that year [<xref ref-type="bibr" rid="CR26">26</xref>].<list list-type="bullet"><list-item><p id="Par20">A. Esophageal cancer</p></list-item></list></p><p id="Par21">Esophageal cancer (EC), a highly invasive cancer, was the eighth most common cancer and the sixth leading cause of cancer-related death in 2020 [<xref ref-type="bibr" rid="CR27">27</xref>]. EC has high mortality rate due to its poor prognosis and remain asymptomatic at early stage and presenting common symptoms including Dysphagia alone or with unintentional weight loss. Adenocarcinomoa and squamous cell carcinoma are the common esophageal cancer and account more than 95% of esophageal cancer [<xref ref-type="bibr" rid="CR28">28</xref>]. Emodin, has diverse biological activity and at first it was thought that it has ability to inhibit protein tyrosine kinase p65<italic>lck</italic>, but now results showing it can interact with many cellular targets and can modulate or inhibit mammalian cell cycle in oncogene over expressed cell suggesting the compound having anti-cancerous property [<xref ref-type="bibr" rid="CR29">29</xref>]. AKT and ERK are signal regulated kinase and observed in many cancerous cells and play important role in cell differentiation, proliferation, and survival. Additionally involved in the TE1cell of esophageal cancer are these kinases, AKT and ERK. Aloe-emodin, which is found in aloe latex, has the capacity to dose-dependently inhibit the phosphorylation of AKT and ERK, suppressing their function and TE1 cell proliferation in the S-phase of the cell cycle, thereby halting the progression of cancer. Therefore, Aloe-emodin can be used in esophageal cancer therapy [<xref ref-type="bibr" rid="CR30">30</xref>]. Similarly, in another study the anti-cancer effect of emodin was evaluated against human esophageal carcinoma cell line ECA109. The results revealed that the emodin induces cell apoptosis in ECA109 cell line and inhibit cell invasion by modulating and down regulating the activation and expression of MMP2, Bax/Bcl-2 and caspase-3 involving in esophageal cancer [<xref ref-type="bibr" rid="CR31">31</xref>]. Emodin has been shown in a related study to cause apoptosis and inhibit the growth of EC9706 cells. When combined with ciplatin, emodin significantly raises intracellular ROS, which improves proapoptotic effects and can be used to treat esophageal cancer [<xref ref-type="bibr" rid="CR32">32</xref>] (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<list list-type="bullet"><list-item><p id="Par22">B. Gastric cancer</p></list-item></list><fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Illustration of emodin mediated apoptosis activation. Emodin can activate the apoptosis of cancer cells by activating intrinsic pathways via increasing the expression of cytochrome C, caspa-9, -3, and via changing the mitochondrial membrane potential; and extrinsic pathway via increasing the expression of death receptor, caspase 8, Bak protein. Emodin can also inhibit NF-kB pathway and decreased ROS production to activate apoptotic cell death. Further, it also inhibits the dimerization of VEGFR2 receptors and inhibit downstream PI3, AKT pathway</p></caption><graphic xlink:href="12672_2025_2240_Fig3_HTML" id="MO3"/></fig></p><p id="Par23">The most prevalent kind of stomach cancer, gastric cancer (GC), has a variety of histological presentations and is still difficult to diagnose and treat. The most prevalent type of gastric cancer, tubular adenocarcinoma, accounts for over half of all cases and has been reported to be as high as 72% in South Korea [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Emodin also effectively used in gastric cancer prevention and treatment. RhoA is a signaling molecule and play important role in gastric cancer and regulating variety of cellular process for the cancer progression. It has been seen that emodin induced reactive oxygen species generation which, inhibit RhoA activation and sensitized gastric cell carcinoma to transform them into anoikis (inappropriate cell&#x02013;matrix interactions) thus inhibiting the proliferation of gastric cancer [<xref ref-type="bibr" rid="CR35">35</xref>]. Helicobacter pylori&#x000a0;is a gram-negative pathogenic bacteria colonize in the 50% human population intestine worldwide and lead to many infections including gastric ulcer, Chronic gastritis, gastric cancer and many more. Eradication of H. pylori from intestine could prevent the development and progression of these diseases [<xref ref-type="bibr" rid="CR36">36</xref>].&#x000a0;Aloe-emodin reported to successfully inhibit the colonization of this bacteria in the intestine and destroy the biofilm formation by H. pylori, thus can be used for the clinical treatment of H. pylori and its associated disease [<xref ref-type="bibr" rid="CR27">27</xref>]. It has also reported that emodin use mitochondrial mediate apoptosis (MMA) mechanism to inhibit GI cancer. The pro- and anti-apoptotic proteins in the mitochondrial membrane are primarily balanced to control MMA. Interestingly, the mitochondria of GI cancer cells have been found to contain emodin at concentrations of 50 and 100&#x000a0;&#x000b5;M [<xref ref-type="bibr" rid="CR37">37</xref>]. The emodin trigger the mitochondria of GI cancer cells to disrupt mitochondrial membrane potential by signaling molecules Bax, Bak PARP and triggers the release of cytochrome c to activate caspase -9 and 3 culminating into apoptosis [<xref ref-type="bibr" rid="CR38">38</xref>]. Emodin along with 5FU is commonly used to cure gastric cancer. Their combination exerts a synergistic effect on inhibiting the proliferation of gastric cell cancer and promotes cell apoptosis [<xref ref-type="bibr" rid="CR32">32</xref>]. It has been also evaluated that alone emodin show weak inhibitory activity on cell proliferation but when it combined with 5FU in a dose dependent manner it significantly increase its impact and restricted cell growth, reduce cell division index, decrease the size of many cells of gastric cancer cell within 48&#x000a0;h of treatment and also allow to differentiate cell line boundaries [<xref ref-type="bibr" rid="CR39">39</xref>] (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<list list-type="bullet"><list-item><p id="Par24">C. Colorectal cancer</p></list-item></list></p><p id="Par25">In both sexes, colorectal cancer (CRC) is the third most common cause of cancer-related deaths and the third most common type of cancer diagnosed in the United States. It accounts second rank in cancer related death in men younger than 50&#x000a0;years. Greater than &#x000bd; cases of all deaths are associated with modifiable risk factors such as sedentary and unhealthy life style (16%), smoking (11%), obesity (5%), unhealthy diet (29%) and excessive alcohol consumption (13%) [<xref ref-type="bibr" rid="CR40">40</xref>]. Emodin also effectively used to treat CRC, as it has ability to inhibit the proliferation of CRC cells by targeting VEGFR2 (vascular endothelial growth factor receptor 2) a signaling pathway. The expression of VEGFR2, p-AKT, and PI3K is significantly high in CRC cells and thus favoring cell proliferation and cancer progression. Emodin bound the hydrophobic pocket of VEGFR2 and inhibiting the dimerization of VEGFR2 and lowers the expression of p-AKT and PI3K in HCT116 cells in vivo and tumor bearing mice [<xref ref-type="bibr" rid="CR41">41</xref>]. Another study reported that emodin regulating Bcl-2/Bax ratio and cytochrome c and can inhibit the proliferation of LOVO colorectal cancer&#x000a0;[<xref ref-type="bibr" rid="CR42">42</xref>]. The ROS/p38/p53/Puma signalling pathway can be regulated by emodin to cause apoptosis in human colorectal cancer cells SW620 and SW480 [<xref ref-type="bibr" rid="CR75">75</xref>], and it can also suppress Wnt signalling in these cells [<xref ref-type="bibr" rid="CR74">74</xref>]. However, the exact way that emodin treats colorectal cancer is unknown. ACSL4 has direct role in CRC development by increasing the expression of VEGFR1 and VEGFR2. Emodin induced pathway exert a signaling pathway that suppress the activation of ACSL4 thus the expression of VEGF secretion system and inhibiting CRC proliferation [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR43">43</xref>] reported that the emodin administration of (40 or 80&#x000a0;mg/kg in AOM/DSS and 80&#x000a0;mg/kg in ApcMin/&#x02009;+) orally thrice per week shows preventive effect. It also reduces the size and polyp count both in rodent models also show lower protumerogenic M2 like macrophages in colon microenvironment and also there is reduced ratio of M2/M1 macrophage within the colon (P&#x02009;&#x0003c;&#x02009;0.05).&#x000a0;Ferroptosis is a novel apoptosis method associated with iron-dependent lipid peroxidation and a promising strategy in cancer treatment. It has been linked that Emodin induce ferroptosis and suppressed tumor growth in xenograft mouse model. Additionally, it was determined that by deactivating the NF-&#x003ba;b pathway in CRC cells, emodin caused ferroptosis via NCOA4-mediated ferritinophagy [<xref ref-type="bibr" rid="CR44">44</xref>] (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<list list-type="bullet"><list-item><p id="Par26">D. Pancreatic cancer</p></list-item></list></p><p id="Par27">Pancreatic cancer (PC) is one of the life threatening cancer and leading cause of cancer linked death in United States [<xref ref-type="bibr" rid="CR45">45</xref>]. The exact cause of PC is not clear but many modifiable and non-modifiable risk factors are linked with PC. The modifiable risk factors include obesity, infection, dietary factors, alcohol consumption, smoking, pancreatitis and socieo- economic status, while the non-modifiable risk factors include gender, age, ABO blood group, ethnicity, microbiota, Diabetes mellitus, genetic susceptibility and family history [<xref ref-type="bibr" rid="CR46">46</xref>]. A range of malignant tumours are directly inhibited by emodin. By preventing EMT (epithelial mesenchymal transition) in tumour cells and inducing tumour cell apoptosis in pancreatic carcinoma cells, micro-RNA-1271 (miRNA 1271) exhibits broad tumor-suppression activity. It also inhibits the growth and metastasis of a number of malignant tumour cells. Through the inhibition of tumour cells&#x02019; EMT and the induction of tumour cell apoptosis, miR 1271 has a broad tumor-suppression effect. Emodin show positive impact on miR 1271 expression thus supporting the tumor cell apoptosis via EMT regulatory mechanism [<xref ref-type="bibr" rid="CR42">42</xref>]. Similarly, over expression of EGFR is closely associated with tumor formation, their progression and deterioration and liked with 90% of the pancreatic cancer. However, drug targeting EGFR inhibitor is the easy way to control disease but drug resistance of EGPR inhibitor making treatment challenging. Though. Emodin surprisingly. Enhanced the anti-cancer effect of EGPR inhibitor on pancreatic carcinoma, it also promote afatinib-induced apoptosis by blocking the STAT 3 signaling pathway [<xref ref-type="bibr" rid="CR47">47</xref>].&#x000a0;Emodin-loaded lipid nano-capsules (M-CS-E-LNC)&#x02014;mannose-conjugated chitosan-coated emodin nano-capsules&#x02014;were used to treat severe acute pancreatitis. The carnitine palmitoyltransferase 1 protein was able to be up-regulated by the emodine nanocapsule, which ultimately facilitated intracellular long-chain fatty acid transport. This led to the M2 phenotype polarization of macrophages and a decrease in the amount of inflammatory mediators in macrophages [<xref ref-type="bibr" rid="CR48">48</xref>]. Emodin based a novel drug delivery system was formulated to treat acute pancreatitis in mouse model. A membrane-coated UiO-66-NH2 that has been loaded with emodin (MVs-UiO-ED). MVs-UiO-ED nanoparticle was found to decrease serum levels of lipase and &#x003b1;-amylase, two important markers of the severity of pancreatitis. Additionally, histopathological analyses demonstrated that MVs-UiO-ED reduced pancreatic tissue damage, and the author's findings support the treatment of acute pancreatitis [<xref ref-type="bibr" rid="CR49">49</xref>] (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<list list-type="bullet"><list-item><p id="Par28">E. Liver cancer</p></list-item></list></p><p id="Par29">Liver is the principal organ in body involve in detoxification of toxic chemicals, pathogens and metabolic waste. The organ is in continuous exposure to viruses, alcohol, bio-transformed metabolites and cholestasis which sometime lead to liver inflammation and liver injury. When injury sustained for long time it culminating into chronic liver disease [<xref ref-type="bibr" rid="CR50">50</xref>]. Emodin, possess antiproliferative and apoptosis effects in many cancer cell lines. In liver cancer, emodin induces apoptosis in HepG2 cells and arrest the cells in their G1 phase. Additionally, it activates CASPASE -8 and CASPASE-9 and causes cytochrome c to be released from mitochondria into the cytosol. Additionally, it raises p53 protein levels and lowers NF-&#x003ba;B/p65 levels in HepG2 cells; these two regulators may be important in HepG2 cell apoptosis induced by emodin [<xref ref-type="bibr" rid="CR51">51</xref>]. Emodin shows promising role in treating HCC by suppressing the growth and movement of HCC cell and also targeting CD&#x02009;+&#x02009;&#x02009;+&#x02009;hepatoma cells by inhibiting its proliferation [<xref ref-type="bibr" rid="CR52">52</xref>]. In another study it has been reported that the emodin play multi role in liver disease. It is able to reduce collagen synthesis, inhibiting oxidative stress thus prevent liver fibrosis, inhibiting TGF-&#x003b2;/Smad pathway and HSCs proliferation and promoting HSCs apoptosis. It also regulates the lipid metabolism in liver thus regulate the oxidation of lipid and cholesterol synthesis and prevent nonalcoholic fatty liver. Emodin also play significant role in inhibiting liver cancer by inducing mitochondrial apoptosis pathway in hepatocellular carcinoma cells [<xref ref-type="bibr" rid="CR53">53</xref>]. According to another study, emodin suppresses transcriptional activity and sterol regulatory element-binding protein-2, which in turn suppresses cholesterol biosynthesis and oncogenic protein kinase B (AKT) signalling. STAT3, or signal transducer and activator of transcription 3, and oncogenic transcription factors are rendered inactive by regulated cholesterol synthesis and oncogenic AKT signalling. Emodin&#x02019;s sensitising effect on sorafenib-based therapy for HCCs was also assessed, and it was found to significantly enhance sorafenib&#x02019;s anti-cancer effect in liver cell cancers, including HepG2, Hep3B, Huh7, SK-HEP-1, and PLC/PRF5. Furthermore, sorafenib and emodin increased apoptosis in HCCs and cell cycle arrest in the G1 phase in a synergistic manner [<xref ref-type="bibr" rid="CR54">54</xref>] (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Various studies focusing on the anticancer effect of emodin have been summarized in Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Anticancer potential of emodin in various types of cancer cell lines and animals</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">S.no</th><th align="left">Type of cancer</th><th align="left">Cell line/animals</th><th align="left">Concentration</th><th align="left">Mechanism</th><th align="left">Reference</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">Hepatic carcinoma</td><td align="left">HepG2 cells</td><td align="left">20&#x02013;200&#x000a0;&#x000b5;M</td><td align="left">Reduces wadburg effect by &#x02193; HKII, PKM2, LDHA, limiting energy supply, &#x02191; ROS production, &#x02191; mitochondrial damage and apoptosis</td><td align="left">[<xref ref-type="bibr" rid="CR55">55</xref>]</td></tr><tr><td align="left">2</td><td align="left">Breast cancer</td><td align="left">SKBR3 cells</td><td align="left">10&#x02013;50&#x000a0;&#x000b5;M</td><td align="left">&#x02191; apoptosis, &#x02191;mRNA expression of caspase 3,8, 9 and Bax, &#x02193; Bcl2 expression</td><td align="left">[<xref ref-type="bibr" rid="CR56">56</xref>]</td></tr><tr><td align="left">3</td><td align="left">Breast cancer</td><td align="left">C57BL/6 Mice</td><td align="left">40&#x000a0;mg/Kg</td><td align="left">&#x02193; TGF- &#x003b2;1 signalling pathway, inhibit transcription factor to EMT and CSC</td><td align="left">[<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td align="left">4</td><td align="left">Lung cancer</td><td align="left">NCSLC cells</td><td align="left">25&#x02013;75&#x000a0;&#x000b5;M</td><td align="left">&#x02193; redox metabolism, &#x02191;ROS levels, &#x02191; DNA damage specific to cancer cells and leading to senescence</td><td align="left">[<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td align="left">5</td><td align="left">Lung cancer</td><td align="left">NCSLC cells</td><td align="left">&#x02013;</td><td align="left">&#x02193; sPLA2-IIa and NF-&#x003ba;B pathways, inhibited mTOR &#x00026; AKT, activated AMPK, &#x02191;apoptosis, cell cycle arrest &#x00026; ROS production</td><td align="left">[<xref ref-type="bibr" rid="CR59">59</xref>]</td></tr><tr><td align="left">6</td><td align="left">Ovarian cancer</td><td align="left">SK-OV-3, A2780, PA-1</td><td align="left">2.5&#x02013;80&#x000a0;&#x000b5;M</td><td align="left">Inhibited EMT by &#x02193; N cadherin &#x00026; vimentin and &#x02191; E-cadherin</td><td align="left">[<xref ref-type="bibr" rid="CR60">60</xref>]</td></tr><tr><td align="left">7</td><td align="left">Cervical cancer</td><td align="left">HeLa cells</td><td align="left">100&#x000a0;&#x000b5;M</td><td align="left">Induction of mitotic catastrophe, inhibited mitosis mainly in metaphase, G2/M phase, &#x02191; apoptosis</td><td align="left">[<xref ref-type="bibr" rid="CR61">61</xref>]</td></tr><tr><td align="left">8</td><td align="left">Breast cancer</td><td align="left">EO771 &#x00026; 4 T1</td><td align="left">50&#x000a0;&#x000b5;M</td><td align="left">Inhibited cellular proliferation &#x00026; migration by &#x02193; CD155</td><td align="left">[<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td align="left">9</td><td align="left">Bladder cancer</td><td align="left">T24 &#x00026; 5637</td><td align="left">20&#x02013;80&#x000a0;&#x000b5;mol/L</td><td align="left">&#x02193; cellular growth, invasion &#x00026; expression of Notch 1, Jagged 1, VEGF, VEGFR2, MMP2</td><td align="left">[<xref ref-type="bibr" rid="CR63">63</xref>]</td></tr><tr><td align="left">10</td><td align="left">Glioma</td><td align="left">C6 &#x00026; U87-MG</td><td align="left">30&#x02013;300&#x000a0;&#x000b5;M</td><td align="left">Deactivates phosphorylated AKT, ceases nuclear translocation of NF-&#x003ba;B, &#x02193; &#x003b2;- Catenin, &#x02191; N-cadherin</td><td align="left">[<xref ref-type="bibr" rid="CR64">64</xref>]</td></tr><tr><td align="left">11</td><td align="left">Glioma</td><td align="left">C6</td><td align="left">&#x02013;</td><td align="left">&#x02193; ERK1/2, &#x02191; Caspase dependent autophagy</td><td align="left">[<xref ref-type="bibr" rid="CR65">65</xref>]</td></tr><tr><td align="left">12</td><td align="left">Glioma</td><td align="left">U87-MG</td><td align="left">20&#x02013;40&#x000a0;&#x000b5;M</td><td align="left">Arrest cell cycle in S &#x00026; G2M phase, &#x02191; PARP and Lamin, &#x02193;pAKT phosphorylation</td><td align="left">[<xref ref-type="bibr" rid="CR66">66</xref>]</td></tr><tr><td align="left">13</td><td align="left">Prostate cancer</td><td align="left">PC3</td><td align="left">20&#x02013;80&#x000a0;&#x000b5;g/ml</td><td align="left">Cell cycle arrest in S &#x00026; G2/M phase, &#x02191; Notch 1, &#x02193; Jagged1, VEGF &#x00026; bFGF</td><td align="left">[<xref ref-type="bibr" rid="CR67">67</xref>]</td></tr><tr><td align="left">14</td><td align="left">Prostate cancer</td><td align="left">PC3</td><td align="left">10&#x02013;40&#x000a0;&#x000b5;mol/L</td><td align="left">&#x02193;Androgen-dependent transactivation, induces androgen receptor degradation</td><td align="left">[<xref ref-type="bibr" rid="CR68">68</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Anticancer effects of emodin on various GI cancers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">S.No</th><th align="left">Type of cancer</th><th align="left">Subjective model</th><th align="left">Physiological effects</th><th align="left">Mechanism of action</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">Esophageal cancer</td><td align="left">ECA109 cells</td><td align="left">&#x02191;Apoptosis</td><td align="left">&#x02193; MMP-2, Bcl-2 &#x00026; &#x02191;expression of Bax and Caspase</td><td align="left">[<xref ref-type="bibr" rid="CR31">31</xref>]</td></tr><tr><td align="left">2</td><td align="left">Esophageal cancer</td><td align="left">TE1 cells</td><td align="left">&#x02193;Proliferation</td><td align="left">&#x02193; Phosphorylation of AKT and ERK</td><td align="left">[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td align="left">3</td><td align="left">Gastric cancer</td><td align="left">SGC-7901 cells</td><td align="left">&#x02193; Proliferation</td><td align="left">&#x02191;Photodynamic activity &#x00026; &#x02191;caspase 9, caspase-3 levels</td><td align="left">[<xref ref-type="bibr" rid="CR69">69</xref>]</td></tr><tr><td align="left">4</td><td align="left">Gastric cancer</td><td align="left">AGS, NCI-N87</td><td align="left">&#x02191; Apoptosis</td><td align="left">&#x02191;Caspase-3 and nuclear shrinkage</td><td align="left">[<xref ref-type="bibr" rid="CR70">70</xref>]</td></tr><tr><td align="left">5</td><td align="left">Gastric cancer</td><td align="left">MKN45</td><td align="left">&#x02193;Proliferation</td><td align="left">Cell cycle arrest at G2/M phase and cell death</td><td align="left">[<xref ref-type="bibr" rid="CR71">71</xref>]</td></tr><tr><td align="left">6</td><td align="left">Gastric cancer</td><td align="left">SGC-7901</td><td align="left">&#x02193;Proliferation and &#x02191;apoptosis</td><td align="left">&#x02193;Expression of Phosphatase of regenerating-3 (PRL-3)</td><td align="left">[<xref ref-type="bibr" rid="CR72">72</xref>]</td></tr><tr><td align="left">7</td><td align="left">Colorectal Cancer</td><td align="left">HCT116 and CRC mouse model</td><td align="left">&#x02193; Proliferation</td><td align="left">&#x02193;VEGF secretion and VEGFR1, VEGFR2 expression by &#x02193;ACSL4</td><td align="left">[<xref ref-type="bibr" rid="CR41">41</xref>]</td></tr><tr><td align="left">8</td><td align="left">Colorectal Cancer</td><td align="left">HCT116 and Xenograft tumor model</td><td align="left">&#x02193;Proliferation</td><td align="left">&#x02193;VEGFR2, PI3K, p-AKT</td><td align="left">[<xref ref-type="bibr" rid="CR73">73</xref>]</td></tr><tr><td align="left">9</td><td align="left">Colorectal Cancer</td><td align="left">SW480 and SW620</td><td align="left">&#x02193;Cellular proliferation, differentiation and apoptosis</td><td align="left">&#x02193; Wnt signalling pathway by &#x02193;TCF/LEF transcriptional activity</td><td align="left">[<xref ref-type="bibr" rid="CR74">74</xref>]</td></tr><tr><td align="left">10</td><td align="left">Colorectal Cancer</td><td align="left">SW480 and SW620</td><td align="left">&#x02191;Apoptosis</td><td align="left">&#x02191;ROS by &#x02191;p38/p53 and puma signaling</td><td align="left">[<xref ref-type="bibr" rid="CR75">75</xref>]</td></tr><tr><td align="left">11</td><td align="left">Pancreatic cancer</td><td align="left">SW1990</td><td align="left">&#x02191; Apoptosis and &#x02193;metastasis</td><td align="left">&#x02193;EMT (Epithelial mesenchymal transition) and invasion by &#x02191;miR-1271</td><td align="left">[<xref ref-type="bibr" rid="CR76">76</xref>]</td></tr><tr><td align="left">12</td><td align="left">Pancreatic cancer</td><td align="left">PANC-1</td><td align="left">&#x02193;Proliferation</td><td align="left">&#x02193;Methylation of p16, RASSF1A, ppENK</td><td align="left">[<xref ref-type="bibr" rid="CR77">77</xref>]</td></tr><tr><td align="left">13</td><td align="left">Pancreatic cancer</td><td align="left">PANC-1 and BxPC-3</td><td align="left">&#x02193;Proliferation</td><td align="left">EGFR &#x02191;phosphorylation of Stat3</td><td align="left">[<xref ref-type="bibr" rid="CR47">47</xref>]</td></tr><tr><td align="left">14</td><td align="left">Pancreatic cancer</td><td align="left">Sw1990 &#x00026; Panc-1</td><td align="left">&#x02191; Apoptosis and &#x02193;angiogenesis</td><td align="left">By &#x02193; NF-&#x003ba;B and &#x02193;VEGF, MMP-2, MMP-9 &#x00026; eNOS Phosphorlyation</td><td align="left">[<xref ref-type="bibr" rid="CR78">78</xref>]</td></tr><tr><td align="left">15</td><td align="left">Liver cancer</td><td align="left">HepG2 cells</td><td align="left">&#x02193;Cellular proliferation</td><td align="left">&#x02193; SMAD <sub>2/4</sub> by &#x02191;miR-34a &#x00026; &#x02193;VEGFR<sub>2</sub>-AKT-ERK<sub>1/2</sub></td><td align="left">[<xref ref-type="bibr" rid="CR79">79</xref>]</td></tr><tr><td align="left">16</td><td align="left">Liver cancer</td><td align="left">SMMC-7721</td><td align="left">&#x02191; Apoptosis</td><td align="left">&#x02191;Phosphorylation of ERK, p38 &#x00026; &#x02193;pAKT</td><td align="left">[<xref ref-type="bibr" rid="CR80">80</xref>]</td></tr><tr><td align="left">17</td><td align="left">Liver cancer</td><td align="left">HepG2 cells</td><td align="left">&#x02193; Proliferation and metastasis</td><td align="left">&#x02191;S and G2/M phase arrest and promotes snail and &#x003b2;-catenin degradation, &#x02193;PI3K/AKT/mTOR</td><td align="left">[<xref ref-type="bibr" rid="CR81">81</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec5"><title>Role of nanotechnology and synergism with emodin</title><p id="Par30">The pharmacokinetic limited properties of emodin significantly affect its bioavailability and bioactivity, hence limiting its therapeutic uses. Nanotechnology based drug carriers have been researched to help get past these obstacles. Studies employing phytochemicals in synergism demonstrated better therapeutic opportunity against growth of cancer. EMO exhibits broader range of pharmacological activities and in combination with nano range molecules. Their physiological properties can be enhanced providing combinatorial effect and as targeted therapy. EMO is derivative of anthraquinone and exhibit lower toxicity and appears to be cheaper. For instance, EMO loaded stearic acid&#x02014;g&#x02014;chitosan oligosaccharide nano-micelles (CSO-SA-EMO) significantly enhanced antioncogenic properties against the gastric cancer cells. The combinatorial CSO-SA-EMO profoundly arrested the MGC803 and BGC823 cells in G2/M phase of cell cycle. The antitumor effect of CSO-SA-EMO compound was proved by HE staining, tumour volume and TUNEL assay against the gastric cancer cells. It also exhibited upright submissive targeting effect in vivo [<xref ref-type="bibr" rid="CR82">82</xref>].</p><p id="Par31">Pancreatic cancer is hard to treat due to lack of atypical symptoms. Emodin as natural economic product with magnetic nanoparticles achieves targeted therapy in pancreatic cancer. EMO loaded Cy7-NHS ester activated PEG coated Fe<sub>3</sub>O<sub>4</sub> (Fe<sub>3</sub>O<sub>4</sub>- PEG-Cy7-EMO) nanoparticles were targeted in vitro and in vivo. The Fe<sub>3</sub>O<sub>4</sub>- PEG-Cy7-EMO nanoparticles showed greater inhibition effect in BxPC-3 cells. The analysis validated that therapeutic effect of Fe<sub>3</sub>O<sub>4</sub>- PEG-Cy7-EMO nanoparticles was greater in BxPC-3 cells than hTERT-HPNE cells. This revealed these nanoparticles combinatorial has more phagocytic ability in pancreatic cancer cells than normal pancreatic cells. The Fe<sub>3</sub>O<sub>4</sub>- PEG-Cy7-EMO nanoparticles also proved potential nanoplatform in pancreatic tumor xenografted mice. Histological analysis of Fe<sub>3</sub>O<sub>4</sub>- PEG-Cy7-EMO nanoparticles was performed in vivo and no pathological changes was observed in heart, liver, kidney and lungs indicates salability to in vivo experiments [<xref ref-type="bibr" rid="CR83">83</xref>]. Thus, nanoparticles in conjugation with EMO demonstrated their potential towards the gastrointestinal cancers as they facilitate treatment efficiently compared to only EMO or nanoparticles. The number studies were conducted in conjugation with EMO and nanoparticles with greater efficiency against gastrointestinal cancers [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>].</p></sec><sec id="Sec6"><title>Safety aspects of emodin</title><p id="Par32">Emodin is generally safe medication, based on data from research using experimental animals. For instance, recent study shows that subchronic (12&#x000a0;week) emodin treatment at a maximum dose of 80&#x000a0;mg/Kg body weight orally and 40&#x000a0;mg/Kg body weight intraperitoneally does not significantly harm patients. In mice of both sexes there is no harm on liver, colon, intestine or cardiovascular system [<xref ref-type="bibr" rid="CR86">86</xref>]. The molecule of emodin is regarded as harmless or safe as due to extensive history of emodin rich plants such as rhubarb and aloe being used by human. Despite of their positive effect on cancers, adverse effect of higher doses are also reported [<xref ref-type="bibr" rid="CR87">87</xref>]. However, emodin dosage higher than 500&#x02013;1500&#x000a0;mg/Kg of body weight may cause toxicity such as hepatotoxicity and inflammation [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR88">88</xref>]. More specifically, it was shown emodin caused Sprague- Dawley rat&#x02019; liver to damage because too much of it collected in the liver cells and hindered the movement of FADH or NADH from cytoplasm to mitochondria and results in activation of mitochondrial apoptosis [<xref ref-type="bibr" rid="CR87">87</xref>]. It is important to acknowledge that majority of emodin toxicity studies had been based upon excessive dosage (far higher than necessary therapeutic levels). Therefore, in-depth evaluations of therapeutic levels of emodin are necessary in both human and experimental animals.</p></sec><sec id="Sec7"><title>Recent trends and future prospective</title><p id="Par33">Emodin demonstrates potent anticancer effects by employing multiple mechanisms, including the suppression of cell proliferation, the activation of apoptotic pathways, and the inhibition of tumor angiogenesis and metastatic processes. Literature reported the use of combinatorial method for number of diseases like acute pancreatitis [<xref ref-type="bibr" rid="CR89">89</xref>], obesity [<xref ref-type="bibr" rid="CR90">90</xref>], bone disorder [<xref ref-type="bibr" rid="CR91">91</xref>], cancer [<xref ref-type="bibr" rid="CR92">92</xref>]. The combinatorial therapy may reduce the chances of drug resistance, side effects and enhances potential of drug. Recent studies exhibited higher potential of use of emodin or emodin analogues with other therapeutic compounds to enhance their efficiency in treatment of various types of cancers [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]. Understanding the intricate relationships between the tumor microenvironment, cancer progression, and immune resistance is crucial for devising optimal therapeutic strategies for all gastrointestinal solid tumors. In the future, it is anticipated that the targeted delivery of emodin could effectively impact gastrointestinal cancer in a predictable and reproducible manner. Additionally, the development of advanced pharmaceutical nanoformulations is crucial to enhance its bioavailability. The translation of anticancer properties of emodin to clinical applications, need further preclincical to clinical studies to evaluate its safety. Emodin is promosing natural compound as therapeutic compound for treatment of GI cancer which warrants further investigation to facilitate development of novel strategy for treatment of GI cancers. Based on current evidence, emodin emerges as a biomolecule with substantial potential for future therapeutic applications.</p></sec><sec id="Sec8"><title>Conclusion</title><p id="Par34">Over past years, alternative therapeutic approaches have increased in response to staggering global rise in cancer incidence and mortality rate. There are tireless efforts made to extend reach of traditional medical procedures such as radiation, chemotherapy, immunotherapy and surgical but global study of nutraceuticals made the impact. Recent research studies have shown significant impression of emodin on progress of GI cancers. The number of studies demonstrated the emodin inhibits the pathways that lead to inflammation, angiogenesis, proliferation, tumorigenesis in addition to mitochondrial mediated apoptosis. Recent research targeting tumor progression in vivo and in vitro has shown encouraging results using emodin. The profile of emodin showed metabolism and absorption of lower doses with not significant toxicity. The intriguing aspect of potential of emodin as a supplementary treatment to traditional chemotherapeutics is its capacity to enhance the efficiency of nanoparticles. In conclusion emodin should be further explored in this area as it has lot of potential to treat GI cancers. Emodin can be used alone or it can be used in combination with nanoparticles to treat GI cancers. In broader sense collaborative research in fields of pharmacology, toxicology, pharmacokinetics and pharmaceutics is required to attain safety and specificity for successful GI treatment.</p></sec><sec id="Sec9" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12672_2025_2240_MOESM1_ESM.jpg"><caption><p>Supplementary material 1.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CRC</term><def><p id="Par2">Colorectal cancer</p></def></def-item><def-item><term>EMT</term><def><p id="Par3">Epithelial-mesenchymal transition</p></def></def-item><def-item><term>EC</term><def><p id="Par4">Esophageal cancer</p></def></def-item><def-item><term>GC</term><def><p id="Par5">Gastric cancer</p></def></def-item><def-item><term>GI</term><def><p id="Par6">Gastrointestinal cancer</p></def></def-item><def-item><term>miRNA 1271</term><def><p id="Par7">Micro-RNA-1271</p></def></def-item><def-item><term>MMA</term><def><p id="Par8">Mitochondrial mediate apoptosis</p></def></def-item><def-item><term>OKS</term><def><p id="Par9">Octaketide synthase</p></def></def-item><def-item><term>PC</term><def><p id="Par10">Pancreatic cancer</p></def></def-item><def-item><term>ROS</term><def><p id="Par11">Reactive oxygen species</p></def></def-item><def-item><term>PKS</term><def><p id="Par12">Type III polyketide synthase</p></def></def-item><def-item><term>VEGFR2</term><def><p id="Par13">Vascular endothelial growth factor receptor 2</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>FT: Writing&#x02014;original draft. BP, RS &#x00026; SG: literature search and editing. US, BJS, BS, SH &#x00026; HST: literature search, review &#x00026; editing FA: Conceptualization, Writing&#x02014;original draft. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by Vellore Institute of Technology. The authors have no source of funding.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par35">It&#x02019;s a review article. So, no ethical approval and no consent from participants is required.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par36">All the authors read and approved the final version of the manuscript. The authors do not want open access to the manuscript. Therefore, we assure you that this manuscript was not send for publication in any other journal.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par37">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Derakhshan</surname><given-names>M</given-names></name><etal/></person-group><article-title>High incidence of adenocarcinoma arising from the right side of the gastric cardia in NW Iran</article-title><source>Gut</source><year>2004</year><volume>53</volume><issue>9</issue><fpage>1262</fpage><lpage>1266</lpage><pub-id pub-id-type="pmid">15306582</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Derakhshan M, et al. High incidence of adenocarcinoma arising from the right side of the gastric cardia in NW Iran. Gut. 2004;53(9):1262&#x02013;6.<pub-id pub-id-type="pmid">15306582</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Vedeld</surname><given-names>HM</given-names></name><name><surname>Goel</surname><given-names>A</given-names></name><name><surname>Lind</surname><given-names>GE</given-names></name></person-group><article-title>Epigenetic biomarkers in gastrointestinal cancers: the current state and clinical perspectives</article-title><source>Semin Cancer Biol</source><year>2018</year><pub-id pub-id-type="doi">10.1016/j.semcancer.2017.12.004</pub-id><pub-id pub-id-type="pmid">29253542</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Vedeld HM, Goel A, Lind GE. Epigenetic biomarkers in gastrointestinal cancers: the current state and clinical perspectives. Semin Cancer Biol. 2018. 10.1016/j.semcancer.2017.12.004.<pub-id pub-id-type="pmid">29253542</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Goodarzi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Worldwide incidence and mortality of colorectal cancer and human development index (HDI): an ecological study</article-title><source>World Cancer Res J</source><year>2019</year><volume>6</volume><fpage>8</fpage></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Goodarzi E, et al. Worldwide incidence and mortality of colorectal cancer and human development index (HDI): an ecological study. World Cancer Res J. 2019;6:8.</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><etal/></person-group><article-title>Overcoming resistance to targeted therapies in gastrointestinal cancers: progress to date and progress to come</article-title><source>Am Soc Clin Oncol Educ Book</source><year>2020</year><volume>40</volume><fpage>161</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">32421451</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Chen C, et al. Overcoming resistance to targeted therapies in gastrointestinal cancers: progress to date and progress to come. Am Soc Clin Oncol Educ Book. 2020;40:161&#x02013;73.<pub-id pub-id-type="pmid">32421451</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Gezici</surname><given-names>S</given-names></name><name><surname>&#x0015e;ekero&#x0011f;lu</surname><given-names>N</given-names></name></person-group><article-title>Current perspectives in the application of medicinal plants against cancer: novel therapeutic agents</article-title><source>Anti-Cancer Agents Med Chem (Former Curr Med Chem-Anti-Cancer Agents)</source><year>2019</year><volume>19</volume><issue>1</issue><fpage>101</fpage><lpage>111</lpage></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Gezici S, &#x0015e;ekero&#x0011f;lu N. Current perspectives in the application of medicinal plants against cancer: novel therapeutic agents. Anti-Cancer Agents Med Chem (Former Curr Med Chem-Anti-Cancer Agents). 2019;19(1):101&#x02013;11.</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>W-T</given-names></name><etal/></person-group><article-title>The distinct mechanisms of the antitumor activity of emodin in different types of cancer</article-title><source>Oncol Rep</source><year>2013</year><volume>30</volume><issue>6</issue><fpage>2555</fpage><lpage>2562</lpage><pub-id pub-id-type="pmid">24065213</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Wei W-T, et al. The distinct mechanisms of the antitumor activity of emodin in different types of cancer. Oncol Rep. 2013;30(6):2555&#x02013;62.<pub-id pub-id-type="pmid">24065213</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>X</given-names></name><etal/></person-group><article-title>Emodin: a review of its pharmacology, toxicity and pharmacokinetics</article-title><source>Phytother Res</source><year>2016</year><volume>30</volume><issue>8</issue><fpage>1207</fpage><lpage>1218</lpage><pub-id pub-id-type="pmid">27188216</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Dong X, et al. Emodin: a review of its pharmacology, toxicity and pharmacokinetics. Phytother Res. 2016;30(8):1207&#x02013;18.<pub-id pub-id-type="pmid">27188216</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Synthesis and biological activity evaluation of emodin quaternary ammonium salt derivatives as potential anticancer agents</article-title><source>Eur J Med Chem</source><year>2012</year><volume>56</volume><fpage>320</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">22921966</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Wang W, et al. Synthesis and biological activity evaluation of emodin quaternary ammonium salt derivatives as potential anticancer agents. Eur J Med Chem. 2012;56:320&#x02013;31.<pub-id pub-id-type="pmid">22921966</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Therapeutic potential of emodin for gastrointestinal cancers</article-title><source>Integr Cancer Ther</source><year>2022</year><volume>21</volume><fpage>15347354211067469</fpage><pub-id pub-id-type="pmid">34984952</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">McDonald SJ, et al. Therapeutic potential of emodin for gastrointestinal cancers. Integr Cancer Ther. 2022;21:15347354211067468.<pub-id pub-id-type="pmid">34984952</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><etal/></person-group><article-title>Comprehensive investigation on the metabolism of emodin both in vivo and in vitro</article-title><source>J Pharm Biomed Anal</source><year>2023</year><volume>223</volume><fpage>115122</fpage><pub-id pub-id-type="pmid">36327583</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Zhou L, et al. Comprehensive investigation on the metabolism of emodin both in vivo and in vitro. J Pharm Biomed Anal. 2023;223:115122.<pub-id pub-id-type="pmid">36327583</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Emodin inhibits inflammation, carcinogenesis, and cancer progression in the AOM/DSS model of colitis-associated intestinal tumorigenesis</article-title><source>Front Oncol</source><year>2021</year><volume>10</volume><fpage>564674</fpage><pub-id pub-id-type="pmid">33489875</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Zhang Y, et al. Emodin inhibits inflammation, carcinogenesis, and cancer progression in the AOM/DSS model of colitis-associated intestinal tumorigenesis. Front Oncol. 2021;10:564674.<pub-id pub-id-type="pmid">33489875</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><etal/></person-group><article-title>The phytochemistry and pharmacology of three Rheum species: a comprehensive review with future perspectives</article-title><source>Phytomedicine</source><year>2024</year><volume>131</volume><fpage>155772</fpage><pub-id pub-id-type="pmid">38852474</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Yang X, et al. The phytochemistry and pharmacology of three Rheum species: a comprehensive review with future perspectives. Phytomedicine. 2024;131:155772.<pub-id pub-id-type="pmid">38852474</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Gender differences in the hepatotoxicity and toxicokinetics of emodin: the potential mechanisms mediated by UGT2B7 and MRP2</article-title><source>Mol Pharm</source><year>2018</year><volume>15</volume><issue>9</issue><fpage>3931</fpage><lpage>3945</lpage><pub-id pub-id-type="pmid">30011215</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Wu L, et al. Gender differences in the hepatotoxicity and toxicokinetics of emodin: the potential mechanisms mediated by UGT2B7 and MRP2. Mol Pharm. 2018;15(9):3931&#x02013;45.<pub-id pub-id-type="pmid">30011215</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Sharifi-Rad</surname><given-names>J</given-names></name><etal/></person-group><article-title>Recent advances in the therapeutic potential of emodin for human health</article-title><source>Biomed Pharmacother</source><year>2022</year><volume>154</volume><fpage>113555</fpage><pub-id pub-id-type="pmid">36027610</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Sharifi-Rad J, et al. Recent advances in the therapeutic potential of emodin for human health. Biomed Pharmacother. 2022;154:113555.<pub-id pub-id-type="pmid">36027610</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Comparative pharmacokinetics and tissue distribution of polydatin, resveratrol, and emodin after oral administration of Huzhang and Huzhang-Guizhi herb-pair extracts to rats</article-title><source>J Ethnopharmacol</source><year>2024</year><volume>318</volume><fpage>117010</fpage><pub-id pub-id-type="pmid">37557937</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Yang J, et al. Comparative pharmacokinetics and tissue distribution of polydatin, resveratrol, and emodin after oral administration of Huzhang and Huzhang-Guizhi herb-pair extracts to rats. J Ethnopharmacol. 2024;318:117010.<pub-id pub-id-type="pmid">37557937</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Sougiannis A-JT. <italic>The use of natural anthraquinone emodin as a primary and complementary therapeutic in the treatment of colorectal cancer</italic>. 2020, University of South Carolina.</mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Emodin promotes apoptosis of human endometrial cancer through regulating the MAPK and PI3K/AKT pathways</article-title><source>Open Life sci</source><year>2019</year><volume>13</volume><issue>1</issue><fpage>489</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">33817118</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Jiang J, et al. Emodin promotes apoptosis of human endometrial cancer through regulating the MAPK and PI3K/AKT pathways. Open Life sci. 2019;13(1):489&#x02013;96.<pub-id pub-id-type="pmid">33817118</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>DO</given-names></name><etal/></person-group><article-title>Epidemiology of bacterial contamination of inert hospital surfaces and equipment in critical and non-critical care units: a Brazilian multicenter study</article-title><source>BioRxiv</source><year>2019</year><volume>102</volume><fpage>793034</fpage></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Rodrigues DO, et al. Epidemiology of bacterial contamination of inert hospital surfaces and equipment in critical and non-critical care units: a Brazilian multicenter study. BioRxiv. 2019;102:793034.</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Mitra</surname><given-names>S</given-names></name><etal/></person-group><article-title>Exploring the journey of emodin as a potential neuroprotective agent: novel therapeutic insights with molecular mechanism of action</article-title><source>Biomed Pharmacother</source><year>2022</year><volume>149</volume><fpage>112877</fpage><pub-id pub-id-type="pmid">35367766</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Mitra S, et al. Exploring the journey of emodin as a potential neuroprotective agent: novel therapeutic insights with molecular mechanism of action. Biomed Pharmacother. 2022;149:112877.<pub-id pub-id-type="pmid">35367766</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>&#x0015e;eker Karatoprak</surname><given-names>G</given-names></name><etal/></person-group><article-title>Advances in understanding the role of aloe emodin and targeted drug delivery systems in cancer</article-title><source>Oxid Med Cell Longev</source><year>2022</year><volume>2022</volume><issue>1</issue><fpage>7928200</fpage><pub-id pub-id-type="pmid">35087619</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">&#x0015e;eker Karatoprak G, et al. Advances in understanding the role of aloe emodin and targeted drug delivery systems in cancer. Oxid Med Cell Longev. 2022;2022(1):7928200.<pub-id pub-id-type="pmid">35087619</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Semwal</surname><given-names>RB</given-names></name><etal/></person-group><article-title>Emodin-A natural anthraquinone derivative with diverse pharmacological activities</article-title><source>Phytochemistry</source><year>2021</year><volume>190</volume><fpage>112854</fpage><pub-id pub-id-type="pmid">34311280</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Semwal RB, et al. Emodin-A natural anthraquinone derivative with diverse pharmacological activities. Phytochemistry. 2021;190:112854.<pub-id pub-id-type="pmid">34311280</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Octaketide synthase from Polygonum cuspidatum implements emodin biosynthesis in Arabidopsis thaliana</article-title><source>Plant Cell Physiol</source><year>2021</year><volume>62</volume><issue>3</issue><fpage>424</fpage><lpage>435</lpage><pub-id pub-id-type="pmid">33537755</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Guo Y, et al. Octaketide synthase from Polygonum cuspidatum implements emodin biosynthesis in Arabidopsis thaliana. Plant Cell Physiol. 2021;62(3):424&#x02013;35.<pub-id pub-id-type="pmid">33537755</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Mund</surname><given-names>NK</given-names></name><name><surname>&#x0010c;ell&#x000e1;rov&#x000e1;</surname><given-names>E</given-names></name></person-group><article-title>Recent advances in the identification of biosynthetic genes and gene clusters of the polyketide-derived pathways for anthraquinone biosynthesis and biotechnological applications</article-title><source>Biotechnol Adv</source><year>2023</year><volume>63</volume><fpage>108104</fpage><pub-id pub-id-type="pmid">36716800</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Mund NK, &#x0010c;ell&#x000e1;rov&#x000e1; E. Recent advances in the identification of biosynthetic genes and gene clusters of the polyketide-derived pathways for anthraquinone biosynthesis and biotechnological applications. Biotechnol Adv. 2023;63:108104.<pub-id pub-id-type="pmid">36716800</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Bisht</surname><given-names>R</given-names></name><etal/></person-group><article-title>An overview of the medicinally important plant type III PKS derived polyketides</article-title><source>Front Plant Sci</source><year>2021</year><volume>12</volume><fpage>746908</fpage><pub-id pub-id-type="pmid">34721474</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Bisht R, et al. An overview of the medicinally important plant type III PKS derived polyketides. Front Plant Sci. 2021;12:746908.<pub-id pub-id-type="pmid">34721474</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>The versatile emodin: a natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers</article-title><source>Int J Biol Sci</source><year>2022</year><volume>18</volume><issue>8</issue><fpage>3498</fpage><pub-id pub-id-type="pmid">35637953</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Zhang Q, et al. The versatile emodin: a natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers. Int J Biol Sci. 2022;18(8):3498.<pub-id pub-id-type="pmid">35637953</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>M</given-names></name><etal/></person-group><article-title>Global burden of 5 major types of gastrointestinal cancer</article-title><source>Gastroenterology</source><year>2020</year><volume>159</volume><issue>1</issue><fpage>335</fpage><lpage>349.e15</lpage><pub-id pub-id-type="pmid">32247694</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Arnold M, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159(1):335-349.e15.<pub-id pub-id-type="pmid">32247694</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X-J</given-names></name><etal/></person-group><article-title>Mechanisms of tumor immunosuppressive microenvironment formation in esophageal cancer</article-title><source>World J Gastroenterol</source><year>2024</year><volume>30</volume><issue>16</issue><fpage>2195</fpage><pub-id pub-id-type="pmid">38690024</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Zhang X-J, et al. Mechanisms of tumor immunosuppressive microenvironment formation in esophageal cancer. World J Gastroenterol. 2024;30(16):2195.<pub-id pub-id-type="pmid">38690024</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Short</surname><given-names>MW</given-names></name><name><surname>Burgers</surname><given-names>KG</given-names></name><name><surname>Fry</surname><given-names>VT</given-names></name></person-group><article-title>Esophageal cancer</article-title><source>Am Fam Phys</source><year>2017</year><volume>95</volume><issue>1</issue><fpage>22</fpage><lpage>28</lpage></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Short MW, Burgers KG, Fry VT. Esophageal cancer. Am Fam Phys. 2017;95(1):22&#x02013;8.</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Srinivas</surname><given-names>G</given-names></name><etal/></person-group><article-title>Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent</article-title><source>Med Res Rev</source><year>2007</year><volume>27</volume><issue>5</issue><fpage>591</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">17019678</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Srinivas G, et al. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev. 2007;27(5):591&#x02013;608.<pub-id pub-id-type="pmid">17019678</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Aloe-emodin suppresses esophageal cancer cell TE1 proliferation by inhibiting AKT and ERK phosphorylation</article-title><source>Oncol Lett</source><year>2016</year><volume>12</volume><issue>3</issue><fpage>2232</fpage><lpage>2238</lpage><pub-id pub-id-type="pmid">27602169</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Chang X, et al. Aloe-emodin suppresses esophageal cancer cell TE1 proliferation by inhibiting AKT and ERK phosphorylation. Oncol Lett. 2016;12(3):2232&#x02013;8.<pub-id pub-id-type="pmid">27602169</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>C</given-names></name><etal/></person-group><article-title>Emodin inhibits proliferation and invasion, and induces apoptosis in human esophageal cancer cell line ECA109</article-title><source>Trop J Pharm Res</source><year>2017</year><volume>16</volume><issue>4</issue><fpage>781</fpage><lpage>785</lpage></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Zhao C, et al. Emodin inhibits proliferation and invasion, and induces apoptosis in human esophageal cancer cell line ECA109. Trop J Pharm Res. 2017;16(4):781&#x02013;5.</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Lai</surname><given-names>Y</given-names></name></person-group><article-title>Recent findings regarding the synergistic effects of emodin and its analogs with other bioactive compounds: insights into new mechanisms</article-title><source>Biomed Pharmacother</source><year>2023</year><volume>162</volume><fpage>114585</fpage><pub-id pub-id-type="pmid">36989724</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Hu Y, Yang L, Lai Y. Recent findings regarding the synergistic effects of emodin and its analogs with other bioactive compounds: insights into new mechanisms. Biomed Pharmacother. 2023;162:114585.<pub-id pub-id-type="pmid">36989724</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Epidemiology of gastric cancer in Korea: trends in incidence and survival based on Korea central cancer registry data (1999&#x02013;2019)</article-title><source>J Gastric Cancer</source><year>2022</year><volume>22</volume><issue>3</issue><fpage>160</fpage><pub-id pub-id-type="pmid">35938363</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Park SH, et al. Epidemiology of gastric cancer in Korea: trends in incidence and survival based on Korea central cancer registry data (1999&#x02013;2019). J Gastric Cancer. 2022;22(3):160.<pub-id pub-id-type="pmid">35938363</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>H</given-names></name><etal/></person-group><article-title>Macroscopy predicts tumor progression in gastric cancer: a retrospective patho-historical analysis based on Napoleon Bonaparte's autopsy report</article-title><source>Dig Liver Dis</source><year>2016</year><volume>48</volume><issue>11</issue><fpage>1378</fpage><lpage>1385</lpage><pub-id pub-id-type="pmid">27522550</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Dawson H, et al. Macroscopy predicts tumor progression in gastric cancer: a retrospective patho-historical analysis based on Napoleon Bonaparte&#x02019;s autopsy report. Dig Liver Dis. 2016;48(11):1378&#x02013;85.<pub-id pub-id-type="pmid">27522550</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>J</given-names></name><etal/></person-group><article-title>Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis</article-title><source>Neoplasia</source><year>2008</year><volume>10</volume><issue>1</issue><fpage>41</fpage><lpage>IN19</lpage><pub-id pub-id-type="pmid">18231637</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Cai J, et al. Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis. Neoplasia. 2008;10(1):41-IN19.<pub-id pub-id-type="pmid">18231637</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Bu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Advances in micro/nanodrug delivery systems for the treatment of Helicobacter pylori infection: From diagnosis to eradication</article-title><source>Appl Mater Today</source><year>2024</year><volume>37</volume><fpage>102138</fpage></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Bu F, et al. Advances in micro/nanodrug delivery systems for the treatment of Helicobacter pylori infection: From diagnosis to eradication. Appl Mater Today. 2024;37:102138.</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Emodin targets mitochondrial cyclophilin D to induce apoptosis in HepG2 cells</article-title><source>Biomed Pharmacother</source><year>2017</year><volume>90</volume><fpage>222</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">28363167</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Zhang L, et al. Emodin targets mitochondrial cyclophilin D to induce apoptosis in HepG2 cells. Biomed Pharmacother. 2017;90:222&#x02013;8.<pub-id pub-id-type="pmid">28363167</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Leibowitz</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name></person-group><article-title>Mitochondrial signaling in cell death via the Bcl-2 family</article-title><source>Cancer Biol Ther</source><year>2010</year><volume>9</volume><issue>6</issue><fpage>417</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">20190564</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Leibowitz B, Yu J. Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol Ther. 2010;9(6):417&#x02013;22.<pub-id pub-id-type="pmid">20190564</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Liang Jun</surname><given-names>LJ</given-names></name><name><surname>Zhao FuSheng</surname><given-names>ZF</given-names></name><name><surname>Wu Geng</surname><given-names>WG</given-names></name></person-group><article-title>Effect of aloe-emodin combined with 5-fluorouracil on the proliferation and apoptosis of human gastric cancer cell line</article-title><source>Chin J Gerontol</source><year>2011</year><volume>31</volume><fpage>3074</fpage><lpage>3076</lpage></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Liang Jun LJ, Zhao FuSheng ZF, Wu Geng WG. Effect of aloe-emodin combined with 5-fluorouracil on the proliferation and apoptosis of human gastric cancer cell line. Chin J Gerontol. 2011;31:3074&#x02013;6.</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Islami</surname><given-names>F</given-names></name><etal/></person-group><article-title>Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States</article-title><source>CA Cancer J Clin</source><year>2018</year><volume>68</volume><issue>1</issue><fpage>31</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">29160902</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Islami F, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68(1):31&#x02013;54.<pub-id pub-id-type="pmid">29160902</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>G</given-names></name><etal/></person-group><article-title>ACSL4 promotes colorectal cancer and is a potential therapeutic target of emodin</article-title><source>Phytomedicine</source><year>2022</year><volume>102</volume><fpage>154149</fpage><pub-id pub-id-type="pmid">35567995</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Dai G, et al. ACSL4 promotes colorectal cancer and is a potential therapeutic target of emodin. Phytomedicine. 2022;102:154149.<pub-id pub-id-type="pmid">35567995</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><etal/></person-group><article-title>Emodin inhibits pancreatic cancer EMT and invasion by up-regulating microRNA-1271</article-title><source>Mol Med Rep</source><year>2018</year><volume>18</volume><issue>3</issue><fpage>3366</fpage><lpage>3374</lpage><pub-id pub-id-type="pmid">30066876</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Li N, et al. Emodin inhibits pancreatic cancer EMT and invasion by up-regulating microRNA-1271. Mol Med Rep. 2018;18(3):3366&#x02013;74.<pub-id pub-id-type="pmid">30066876</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Sougiannis</surname><given-names>AT</given-names></name><etal/></person-group><article-title>Emodin reduces tumor burden by diminishing M2-like macrophages in colorectal cancer</article-title><source>Am J Physiol Gastroint Liver Physiol</source><year>2022</year><volume>322</volume><issue>3</issue><fpage>G383</fpage><lpage>G395</lpage></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Sougiannis AT, et al. Emodin reduces tumor burden by diminishing M2-like macrophages in colorectal cancer. Am J Physiol Gastroint Liver Physiol. 2022;322(3):G383&#x02013;95.</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Emodin induces ferroptosis in colorectal cancer through NCOA4-mediated ferritinophagy and NF-&#x003ba;b pathway inactivation</article-title><source>Apoptosis</source><year>2024</year><volume>29</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">37794219</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Shen Z, et al. Emodin induces ferroptosis in colorectal cancer through NCOA4-mediated ferritinophagy and NF-&#x003ba;b pathway inactivation. Apoptosis. 2024;29:1&#x02013;14.<pub-id pub-id-type="pmid">37794219</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Kolbeinsson</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Pancreatic cancer: a review of current treatment and novel therapies</article-title><source>J Invest Surg</source><year>2023</year><volume>36</volume><issue>1</issue><fpage>2129884</fpage><pub-id pub-id-type="pmid">36191926</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Kolbeinsson HM, et al. Pancreatic cancer: a review of current treatment and novel therapies. J Invest Surg. 2023;36(1):2129884.<pub-id pub-id-type="pmid">36191926</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J-X</given-names></name><etal/></person-group><article-title>Pancreatic cancer: a review of epidemiology, trend, and risk factors</article-title><source>World J Gastroenterol</source><year>2021</year><volume>27</volume><issue>27</issue><fpage>4298</fpage><pub-id pub-id-type="pmid">34366606</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Hu J-X, et al. Pancreatic cancer: a review of epidemiology, trend, and risk factors. World J Gastroenterol. 2021;27(27):4298.<pub-id pub-id-type="pmid">34366606</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Emodin sensitizes human pancreatic cancer cells to EGFR inhibitor through suppressing Stat3 signaling pathway</article-title><source>Cancer Manag Res</source><year>2019</year><volume>1</volume><fpage>8463</fpage><lpage>8473</lpage></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Wang Z, et al. Emodin sensitizes human pancreatic cancer cells to EGFR inhibitor through suppressing Stat3 signaling pathway. Cancer Manag Res. 2019;1:8463&#x02013;73.</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>H</given-names></name><etal/></person-group><article-title>Emodin nanocapsules inhibit acute pancreatitis by regulating lipid metabolic reprogramming in macrophage polarization</article-title><source>Phytomedicine</source><year>2024</year><volume>130</volume><fpage>155763</fpage><pub-id pub-id-type="pmid">38820661</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Song H, et al. Emodin nanocapsules inhibit acute pancreatitis by regulating lipid metabolic reprogramming in macrophage polarization. Phytomedicine. 2024;130:155763.<pub-id pub-id-type="pmid">38820661</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Biomimetic delivery of emodin via macrophage membrane-coated UiO-66-NH2 nanoparticles for acute pancreatitis treatment</article-title><source>Biochem Biophys Res Commun</source><year>2024</year><volume>702</volume><fpage>149649</fpage><pub-id pub-id-type="pmid">38341924</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Yang L, et al. Biomimetic delivery of emodin via macrophage membrane-coated UiO-66-NH2 nanoparticles for acute pancreatitis treatment. Biochem Biophys Res Commun. 2024;702:149649.<pub-id pub-id-type="pmid">38341924</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>R</given-names></name><name><surname>Mitra</surname><given-names>A</given-names></name></person-group><article-title>An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer</article-title><source>Int Immunopharmacol</source><year>2015</year><volume>24</volume><issue>2</issue><fpage>335</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">25560752</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Chatterjee R, Mitra A. An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer. Int Immunopharmacol. 2015;24(2):335&#x02013;45.<pub-id pub-id-type="pmid">25560752</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>JQ</given-names></name><name><surname>Bao</surname><given-names>W</given-names></name><name><surname>Lei</surname><given-names>JC</given-names></name></person-group><article-title>Emodin regulates apoptotic pathway in human liver cancer cells</article-title><source>Phytother Res</source><year>2013</year><volume>27</volume><issue>2</issue><fpage>251</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">22565822</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Yu JQ, Bao W, Lei JC. Emodin regulates apoptotic pathway in human liver cancer cells. Phytother Res. 2013;27(2):251&#x02013;7.<pub-id pub-id-type="pmid">22565822</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Emodin is a potential drug targeting CD44-positive hepatocellular cancer</article-title><source>Curr Cancer Drug Targets</source><year>2024</year><volume>24</volume><issue>5</issue><fpage>510</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">38099524</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Gao Y, et al. Emodin is a potential drug targeting CD44-positive hepatocellular cancer. Curr Cancer Drug Targets. 2024;24(5):510&#x02013;8.<pub-id pub-id-type="pmid">38099524</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>N</given-names></name><etal/></person-group><article-title>The effect of emodin on liver disease&#x02013;comprehensive advances in molecular mechanisms</article-title><source>Eur J Pharmacol</source><year>2020</year><volume>882</volume><fpage>173269</fpage><pub-id pub-id-type="pmid">32553811</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Hu N, et al. The effect of emodin on liver disease&#x02013;comprehensive advances in molecular mechanisms. Eur J Pharmacol. 2020;882:173269.<pub-id pub-id-type="pmid">32553811</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y-S</given-names></name><etal/></person-group><article-title>Emodin sensitizes hepatocellular carcinoma cells to the anti-cancer effect of sorafenib through suppression of cholesterol metabolism</article-title><source>Int J Mol Sci</source><year>2018</year><volume>19</volume><issue>10</issue><fpage>3127</fpage><pub-id pub-id-type="pmid">30321984</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Kim Y-S, et al. Emodin sensitizes hepatocellular carcinoma cells to the anti-cancer effect of sorafenib through suppression of cholesterol metabolism. Int J Mol Sci. 2018;19(10):3127.<pub-id pub-id-type="pmid">30321984</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>Y-X</given-names></name><etal/></person-group><article-title>Anti-cancer effects of emodin on HepG2 cells as revealed by 1H NMR based metabolic profiling</article-title><source>J Proteome Res</source><year>2018</year><volume>17</volume><issue>5</issue><fpage>1943</fpage><lpage>1952</lpage><pub-id pub-id-type="pmid">29676152</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Xing Y-X, et al. Anti-cancer effects of emodin on HepG2 cells as revealed by 1H NMR based metabolic profiling. J Proteome Res. 2018;17(5):1943&#x02013;52.<pub-id pub-id-type="pmid">29676152</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Kalkhoran</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Cytotoxic effect of emodin on growth of SKBR3 breast cancer cells</article-title><source>Int J Cancer Manag</source><year>2017</year><pub-id pub-id-type="doi">10.5812/ijcm.8094</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Kalkhoran MR, et al. Cytotoxic effect of emodin on growth of SKBR3 breast cancer cells. Int J Cancer Manag. 2017. 10.5812/ijcm.8094.</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Emodin reduces breast cancer lung metastasis by suppressing macrophage-induced breast cancer cell epithelial-mesenchymal transition and cancer stem cell formation</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><issue>18</issue><fpage>8365</fpage><pub-id pub-id-type="pmid">32724475</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Liu Q, et al. Emodin reduces breast cancer lung metastasis by suppressing macrophage-induced breast cancer cell epithelial-mesenchymal transition and cancer stem cell formation. Theranostics. 2020;10(18):8365.<pub-id pub-id-type="pmid">32724475</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Wahi</surname><given-names>D</given-names></name><name><surname>Soni</surname><given-names>D</given-names></name><name><surname>Grover</surname><given-names>A</given-names></name></person-group><article-title>A double-edged sword: the anti-cancer effects of emodin by inhibiting the redox-protective protein MTH1 and augmenting ROS in NSCLC</article-title><source>J Cancer</source><year>2021</year><volume>12</volume><issue>3</issue><fpage>652</fpage><pub-id pub-id-type="pmid">33403025</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Wahi D, Soni D, Grover A. A double-edged sword: the anti-cancer effects of emodin by inhibiting the redox-protective protein MTH1 and augmenting ROS in NSCLC. J Cancer. 2021;12(3):652.<pub-id pub-id-type="pmid">33403025</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F-Y</given-names></name><etal/></person-group><article-title>Emodin induces apoptosis and suppresses non-small-cell lung cancer growth via downregulation of sPLA2-IIa</article-title><source>Phytomedicine</source><year>2022</year><volume>95</volume><fpage>153786</fpage><pub-id pub-id-type="pmid">34785104</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Zhang F-Y, et al. Emodin induces apoptosis and suppresses non-small-cell lung cancer growth via downregulation of sPLA2-IIa. Phytomedicine. 2022;95:153786.<pub-id pub-id-type="pmid">34785104</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>H</given-names></name><etal/></person-group><article-title>Emodin exerts antitumor effects in ovarian cancer cell lines by preventing the development of cancer stem cells via epithelial mesenchymal transition</article-title><source>Oncol Lett</source><year>2022</year><volume>23</volume><issue>3</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">34820000</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Long H, et al. Emodin exerts antitumor effects in ovarian cancer cell lines by preventing the development of cancer stem cells via epithelial mesenchymal transition. Oncol Lett. 2022;23(3):1&#x02013;10.<pub-id pub-id-type="pmid">34820000</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Trybus</surname><given-names>W</given-names></name><etal/></person-group><article-title>Emodin induces death in human cervical cancer cells through mitotic catastrophe</article-title><source>Anticancer Res</source><year>2019</year><volume>39</volume><issue>2</issue><fpage>679</fpage><lpage>686</lpage><pub-id pub-id-type="pmid">30711945</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Trybus W, et al. Emodin induces death in human cervical cancer cells through mitotic catastrophe. Anticancer Res. 2019;39(2):679&#x02013;86.<pub-id pub-id-type="pmid">30711945</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Anticancer activity of emodin is associated with downregulation of CD155</article-title><source>Int Immunopharmacol</source><year>2019</year><volume>75</volume><fpage>105763</fpage><pub-id pub-id-type="pmid">31325728</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Fang L, et al. Anticancer activity of emodin is associated with downregulation of CD155. Int Immunopharmacol. 2019;75:105763.<pub-id pub-id-type="pmid">31325728</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L</given-names></name><etal/></person-group><article-title>Emodin inhibits the proliferation and invasion of bladder cancer cells via down-regulating Notch1</article-title><source>Int J Clin Exp Pathol</source><year>2017</year><volume>10</volume><issue>9</issue><fpage>9452</fpage><pub-id pub-id-type="pmid">31966818</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Ma L, et al. Emodin inhibits the proliferation and invasion of bladder cancer cells via down-regulating Notch1. Int J Clin Exp Pathol. 2017;10(9):9452.<pub-id pub-id-type="pmid">31966818</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Mir</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Emodin modulates PI3K-AKT pathway to inhibit proliferation, invasion and induce apoptosis in glioma cells</article-title><source>bioRxiv</source><year>2024</year><volume>38</volume><fpage>591</fpage></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Mir AH, et al. Emodin modulates PI3K-AKT pathway to inhibit proliferation, invasion and induce apoptosis in glioma cells. bioRxiv. 2024;38:591.</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Mijatovic</surname><given-names>S</given-names></name><etal/></person-group><article-title>Anti-glioma action of aloe emodin: the role of ERK inhibition</article-title><source>Cell Mol Life Sci</source><year>2005</year><volume>62</volume><fpage>589</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">15747063</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Mijatovic S, et al. Anti-glioma action of aloe emodin: the role of ERK inhibition. Cell Mol Life Sci. 2005;62:589&#x02013;98.<pub-id pub-id-type="pmid">15747063</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Arcella</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effects of aloe emodin on U87MG glioblastoma cell growth: In vitro and in vivo study</article-title><source>Environ Toxicol</source><year>2018</year><volume>33</volume><issue>11</issue><fpage>1160</fpage><lpage>1167</lpage><pub-id pub-id-type="pmid">30218594</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Arcella A, et al. Effects of aloe emodin on U87MG glioblastoma cell growth: In vitro and in vivo study. Environ Toxicol. 2018;33(11):1160&#x02013;7.<pub-id pub-id-type="pmid">30218594</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>G</given-names></name><etal/></person-group><article-title>Emodin inhibits the proliferation of PC3 prostate cancer cells in vitro via the Notch signaling pathway</article-title><source>Mol Med Rep</source><year>2015</year><volume>12</volume><issue>3</issue><fpage>4427</fpage><lpage>4433</lpage><pub-id pub-id-type="pmid">26081222</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Deng G, et al. Emodin inhibits the proliferation of PC3 prostate cancer cells in vitro via the Notch signaling pathway. Mol Med Rep. 2015;12(3):4427&#x02013;33.<pub-id pub-id-type="pmid">26081222</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Cha</surname><given-names>T-L</given-names></name><etal/></person-group><article-title>Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth</article-title><source>Can Res</source><year>2005</year><volume>65</volume><issue>6</issue><fpage>2287</fpage><lpage>2295</lpage></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Cha T-L, et al. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Can Res. 2005;65(6):2287&#x02013;95.</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>HD</given-names></name><etal/></person-group><article-title>The effect of aloe-emodin-induced photodynamic activity on the apoptosis of human gastric cancer cells: a pilot study</article-title><source>Oncol Lett</source><year>2017</year><volume>13</volume><issue>5</issue><fpage>3431</fpage><lpage>3436</lpage><pub-id pub-id-type="pmid">28521449</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Lin HD, et al. The effect of aloe-emodin-induced photodynamic activity on the apoptosis of human gastric cancer cells: a pilot study. Oncol Lett. 2017;13(5):3431&#x02013;6.<pub-id pub-id-type="pmid">28521449</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S-H</given-names></name><etal/></person-group><article-title>Aloe-emodin-induced apoptosis in human gastric carcinoma cells</article-title><source>Food Chem Toxicol</source><year>2007</year><volume>45</volume><issue>11</issue><fpage>2296</fpage><lpage>2303</lpage><pub-id pub-id-type="pmid">17637488</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Chen S-H, et al. Aloe-emodin-induced apoptosis in human gastric carcinoma cells. Food Chem Toxicol. 2007;45(11):2296&#x02013;303.<pub-id pub-id-type="pmid">17637488</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Chihara</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effects of aloe-emodin and emodin on proliferation of the MKN45 human gastric cancer cell line</article-title><source>Asian Pac J Cancer Prev</source><year>2015</year><volume>16</volume><issue>9</issue><fpage>3887</fpage><lpage>3891</lpage><pub-id pub-id-type="pmid">25987055</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Chihara T, et al. Effects of aloe-emodin and emodin on proliferation of the MKN45 human gastric cancer cell line. Asian Pac J Cancer Prev. 2015;16(9):3887&#x02013;91.<pub-id pub-id-type="pmid">25987055</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Z-H</given-names></name><name><surname>Bu</surname><given-names>P</given-names></name></person-group><article-title>Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line</article-title><source>Exp Ther Med</source><year>2012</year><volume>3</volume><issue>6</issue><fpage>1077</fpage><lpage>1081</lpage><pub-id pub-id-type="pmid">22970020</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Sun Z-H, Bu P. Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line. Exp Ther Med. 2012;3(6):1077&#x02013;81.<pub-id pub-id-type="pmid">22970020</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>G</given-names></name><etal/></person-group><article-title>Emodin suppresses growth and invasion of colorectal cancer cells by inhibiting VEGFR2</article-title><source>Eur J Pharmacol</source><year>2019</year><volume>859</volume><fpage>172525</fpage><pub-id pub-id-type="pmid">31288005</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Dai G, et al. Emodin suppresses growth and invasion of colorectal cancer cells by inhibiting VEGFR2. Eur J Pharmacol. 2019;859:172525.<pub-id pub-id-type="pmid">31288005</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Pooja</surname><given-names>T</given-names></name><name><surname>Karunagaran</surname><given-names>D</given-names></name></person-group><article-title>Emodin suppresses Wnt signaling in human colorectal cancer cells SW480 and SW620</article-title><source>Eur J Pharmacol</source><year>2014</year><volume>742</volume><fpage>55</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">25205133</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Pooja T, Karunagaran D. Emodin suppresses Wnt signaling in human colorectal cancer cells SW480 and SW620. Eur J Pharmacol. 2014;742:55&#x02013;64.<pub-id pub-id-type="pmid">25205133</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><etal/></person-group><article-title>ROS/p38/p53/Puma signaling pathway is involved in emodin-induced apoptosis of human colorectal cancer cells</article-title><source>Int J Clin Exp Med</source><year>2015</year><volume>8</volume><issue>9</issue><fpage>15413</fpage><pub-id pub-id-type="pmid">26629030</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Liu B, et al. ROS/p38/p53/Puma signaling pathway is involved in emodin-induced apoptosis of human colorectal cancer cells. Int J Clin Exp Med. 2015;8(9):15413.<pub-id pub-id-type="pmid">26629030</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><etal/></person-group><article-title>Selenoprotein K mediates the proliferation, migration, and invasion of human choriocarcinoma cells by negatively regulating human chorionic gonadotropin expression via ERK, p38 MAPK, and Akt signaling pathway</article-title><source>Biol Trace Elem Res</source><year>2018</year><volume>184</volume><fpage>47</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">28983820</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Li M, et al. Selenoprotein K mediates the proliferation, migration, and invasion of human choriocarcinoma cells by negatively regulating human chorionic gonadotropin expression via ERK, p38 MAPK, and Akt signaling pathway. Biol Trace Elem Res. 2018;184:47&#x02013;59.<pub-id pub-id-type="pmid">28983820</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Effects of emodin on the demethylation of tumor-suppressor genes in pancreatic cancer PANC-1 cells</article-title><source>Oncol Rep</source><year>2015</year><volume>33</volume><issue>6</issue><fpage>3015</fpage><lpage>3023</lpage><pub-id pub-id-type="pmid">25891176</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Zhang H, et al. Effects of emodin on the demethylation of tumor-suppressor genes in pancreatic cancer PANC-1 cells. Oncol Rep. 2015;33(6):3015&#x02013;23.<pub-id pub-id-type="pmid">25891176</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>S-Z</given-names></name><etal/></person-group><article-title>Antitumor activity of emodin against pancreatic cancer depends on its dual role: promotion of apoptosis and suppression of angiogenesis</article-title><source>PLoS ONE</source><year>2012</year><pub-id pub-id-type="doi">10.1371/journal.pone.0042146</pub-id><pub-id pub-id-type="pmid">23300854</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Lin S-Z, et al. Antitumor activity of emodin against pancreatic cancer depends on its dual role: promotion of apoptosis and suppression of angiogenesis. PLoS ONE. 2012. 10.1371/journal.pone.0042146.<pub-id pub-id-type="pmid">23300854</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>J</given-names></name><etal/></person-group><article-title>Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR 2 and miR-34a</article-title><source>Invest New Drugs</source><year>2020</year><volume>38</volume><fpage>229</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">30976957</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Bai J, et al. Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR 2 and miR-34a. Invest New Drugs. 2020;38:229&#x02013;45.<pub-id pub-id-type="pmid">30976957</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>W</given-names></name><etal/></person-group><article-title>Emodin induces hepatocellular carcinoma cell apoptosis through MAPK and PI3K/AKT signaling pathways in vitro and in vivo</article-title><source>Oncol Rep</source><year>2016</year><volume>36</volume><issue>2</issue><fpage>961</fpage><lpage>967</lpage><pub-id pub-id-type="pmid">27278720</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Lin W, et al. Emodin induces hepatocellular carcinoma cell apoptosis through MAPK and PI3K/AKT signaling pathways in vitro and in vivo. Oncol Rep. 2016;36(2):961&#x02013;7.<pub-id pub-id-type="pmid">27278720</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>B</given-names></name><etal/></person-group><article-title>Emodin inhibits invasion and migration of hepatocellular carcinoma cells via regulating autophagy-mediated degradation of snail and &#x003b2;-catenin</article-title><source>BMC Cancer</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>671</fpage><pub-id pub-id-type="pmid">35715752</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Qin B, et al. Emodin inhibits invasion and migration of hepatocellular carcinoma cells via regulating autophagy-mediated degradation of snail and &#x003b2;-catenin. BMC Cancer. 2022;22(1):671.<pub-id pub-id-type="pmid">35715752</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Preparation and evaluation of novel emodin-loaded stearic acid-g-chitosan oligosaccharide nanomicelles</article-title><source>Nanoscale Res Lett</source><year>2020</year><volume>15</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">31897852</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Jiang X, et al. Preparation and evaluation of novel emodin-loaded stearic acid-g-chitosan oligosaccharide nanomicelles. Nanoscale Res Lett. 2020;15:1&#x02013;11.<pub-id pub-id-type="pmid">31897852</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>S</given-names></name><etal/></person-group><article-title>Emodin-conjugated PEGylation of Fe3O4 nanoparticles for FI/MRI dual-modal imaging and therapy in pancreatic cancer</article-title><source>Int J Nanomed</source><year>2021</year><volume>16</volume><fpage>7463</fpage><lpage>7478</lpage></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Ren S, et al. Emodin-conjugated PEGylation of Fe3O4 nanoparticles for FI/MRI dual-modal imaging and therapy in pancreatic cancer. Int J Nanomed. 2021;16:7463&#x02013;78.</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>J&#x000e4;nicke</surname><given-names>P</given-names></name><etal/></person-group><article-title>Fluorescent spherical mesoporous silica nanoparticles loaded with emodin: synthesis, cellular uptake and anticancer activity</article-title><source>Mater Sci Eng, C</source><year>2021</year><volume>119</volume><fpage>111619</fpage></element-citation><mixed-citation id="mc-CR84" publication-type="journal">J&#x000e4;nicke P, et al. Fluorescent spherical mesoporous silica nanoparticles loaded with emodin: synthesis, cellular uptake and anticancer activity. Mater Sci Eng, C. 2021;119:111619.</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Karatoprak</surname><given-names>G&#x0015e;</given-names></name><etal/></person-group><article-title>Advances in understanding the role of aloe emodin and targeted drug delivery systems in cancer</article-title><source>Oxid Med Cell Longev</source><year>2022</year><volume>2022</volume><fpage>1</fpage><lpage>20</lpage></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Karatoprak G&#x0015e;, et al. Advances in understanding the role of aloe emodin and targeted drug delivery systems in cancer. Oxid Med Cell Longev. 2022;2022:1&#x02013;20.</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Sougiannis</surname><given-names>AT</given-names></name><etal/></person-group><article-title>Safety of natural anthraquinone emodin: an assessment in mice</article-title><source>BMC Pharmacol Toxicol</source><year>2021</year><volume>22</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">33407916</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Sougiannis AT, et al. Safety of natural anthraquinone emodin: an assessment in mice. BMC Pharmacol Toxicol. 2021;22:1&#x02013;12.<pub-id pub-id-type="pmid">33407916</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Emodin induces liver injury by inhibiting the key enzymes of FADH/NADPH transport in rat liver</article-title><source>Toxicol Res</source><year>2018</year><volume>7</volume><issue>5</issue><fpage>888</fpage><lpage>896</lpage></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Yang X, et al. Emodin induces liver injury by inhibiting the key enzymes of FADH/NADPH transport in rat liver. Toxicol Res. 2018;7(5):888&#x02013;96.</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Proteomics unravels emodin causes liver oxidative damage elicited by mitochondrial dysfunction</article-title><source>Front Pharmacol</source><year>2020</year><volume>11</volume><fpage>517846</fpage></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Zhang Y, et al. Proteomics unravels emodin causes liver oxidative damage elicited by mitochondrial dysfunction. Front Pharmacol. 2020;11:517846.</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z-F</given-names></name><etal/></person-group><article-title>Emodin and baicalein inhibit pancreatic stromal derived factor-1 expression in rats with acute pancreatitis</article-title><source>Hepatobiliary Pancreat Dis Int HBPD INT</source><year>2009</year><volume>8</volume><issue>2</issue><fpage>201</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">19357036</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Li Z-F, et al. Emodin and baicalein inhibit pancreatic stromal derived factor-1 expression in rats with acute pancreatitis. Hepatobiliary Pancreat Dis Int HBPD INT. 2009;8(2):201&#x02013;8.<pub-id pub-id-type="pmid">19357036</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>X</given-names></name><etal/></person-group><article-title>Synergistic interactions of apigenin, naringin, quercetin and emodin on inhibition of 3T3-L1 preadipocyte differentiation and pancreas lipase activity</article-title><source>Obes Res Clin Pract</source><year>2016</year><volume>10</volume><issue>3</issue><fpage>327</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">26314502</pub-id>
</element-citation><mixed-citation id="mc-CR90" publication-type="journal">Guo X, et al. Synergistic interactions of apigenin, naringin, quercetin and emodin on inhibition of 3T3-L1 preadipocyte differentiation and pancreas lipase activity. Obes Res Clin Pract. 2016;10(3):327&#x02013;39.<pub-id pub-id-type="pmid">26314502</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Emodin promotes the osteogenesis of MC3T3-E1 cells via BMP-9/Smad pathway and exerts a preventive effect in ovariectomized rats</article-title><source>Acta Biochim Biophys Sin</source><year>2017</year><volume>49</volume><issue>10</issue><fpage>867</fpage><lpage>878</lpage><pub-id pub-id-type="pmid">28981600</pub-id>
</element-citation><mixed-citation id="mc-CR91" publication-type="journal">Chen X, et al. Emodin promotes the osteogenesis of MC3T3-E1 cells via BMP-9/Smad pathway and exerts a preventive effect in ovariectomized rats. Acta Biochim Biophys Sin. 2017;49(10):867&#x02013;78.<pub-id pub-id-type="pmid">28981600</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name><surname>Hosseini-Zare</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Synergistic effects of curcumin and its analogs with other bioactive compounds: a comprehensive review</article-title><source>Eur J Med Chem</source><year>2021</year><volume>210</volume><fpage>113072</fpage><pub-id pub-id-type="pmid">33310285</pub-id>
</element-citation><mixed-citation id="mc-CR92" publication-type="journal">Hosseini-Zare MS, et al. Synergistic effects of curcumin and its analogs with other bioactive compounds: a comprehensive review. Eur J Med Chem. 2021;210:113072.<pub-id pub-id-type="pmid">33310285</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>F-P</given-names></name><etal/></person-group><article-title>Emodin enhances the demethylation by 5-Aza-CdR of pancreatic cancer cell tumor-suppressor genes P16, RASSF1A and ppENK</article-title><source>Oncol Rep</source><year>2016</year><volume>35</volume><issue>4</issue><fpage>1941</fpage><lpage>1949</lpage><pub-id pub-id-type="pmid">26782786</pub-id>
</element-citation><mixed-citation id="mc-CR93" publication-type="journal">Pan F-P, et al. Emodin enhances the demethylation by 5-Aza-CdR of pancreatic cancer cell tumor-suppressor genes P16, RASSF1A and ppENK. Oncol Rep. 2016;35(4):1941&#x02013;9.<pub-id pub-id-type="pmid">26782786</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name><surname>Ponnusamy</surname><given-names>L</given-names></name><name><surname>Kothandan</surname><given-names>G</given-names></name><name><surname>Manoharan</surname><given-names>R</given-names></name></person-group><article-title>Berberine and Emodin abrogates breast cancer growth and facilitates apoptosis through inactivation of SIK3-induced mTOR and Akt signaling pathway</article-title><source>Biochim et Biophys Acta (BBA) Mol Basis Dis</source><year>2020</year><volume>1866</volume><issue>11</issue><fpage>165897</fpage></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Ponnusamy L, Kothandan G, Manoharan R. Berberine and Emodin abrogates breast cancer growth and facilitates apoptosis through inactivation of SIK3-induced mTOR and Akt signaling pathway. Biochim et Biophys Acta (BBA) Mol Basis Dis. 2020;1866(11):165897.</mixed-citation></citation-alternatives></ref></ref-list></back></article>